Skip to main content

Table 4 SUVmax and tumour-to-liver ratio for the liver and lymph nodes, by combination

From: A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial

  Arm A (N = 8) Arm B (N = 8) Arm C (N = 8)
Organ Statistic 5–20 µg
40–80 MBq
30–45 µg
100–140 MBq
5–20 µg
100–140 MBq
30–45 µg
160–200 MBq
5–20 µg
160–200 MBq
30–45 µg
40–80 MBq
SUVmax
 Liver n 5 5 5 5 8 8
Median (range) 24.2 (18.25–49.16) 22.9 (18.01–59.83) 9.5 (6.74–63.68) 16.0 (9.56–78.43) 12.4 (6.95–30.07) 17.7 (10.62–30.28)
 Lymph nodes n 3 3 6 6 5 5
Median (range) 24.7 (19.52–40.74) 35.7 (16.69–41.11) 28.5 (9.03–83.06) 27.7 (5.25–53.79) 13.8 (6.08–21.73) 12.7 (6.15–21.33)
Tumour-to-liver ratio (SUVmax/SUVmean)
 Liver n 5 5 5 5 8 8
Median (range) 9.9 (8.51–37.00) 8.4 (7.27–28.31) 6.0 (4.85–40.14) 7.0 (5.08–48.79) 7.2 (3.28–17.98) 9.3 (5.60–32.37)
 Lymph nodes n 3 3 6 6 5 5
Median (range) 18.6 (6.17–27.43) 16.9 (4.83–21.50) 9.9 (4.42–26.46) 13.6 (2.26–25.14) 9.8 (5.30–20.45) 8.2 (5.56–28.98)
  1. n corresponds to the number of patients with lesions in either the liver or the lymph nodes
  2. The number of patients with lesions in the bones, lungs, and the primary tumour site was too small (≤ 3 in each category) to allow a meaningful interpretation of PET/CT scans for these organs
  3. CT computed tomography, PET positron emission tomography, SUV standardised uptake value